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Abstract: Background: Cutaneous squamous cell carcinoma (cSCC) incidence continues to rise with
increasing morbidity and mortality, with limited treatment options for advanced disease. Future
improvements in targeted therapy will rely on advances in genomic/transcriptomic understanding
and the use of model systems for basic research. We describe here the panel of 16 primary and
metastatic cSCC cell lines developed and characterised over the past three decades in our laboratory in
order to provide such a resource for future preclinical research and drug screening. Methods: Primary
keratinocytes were isolated from cSCC tumours and metastases, and cell lines were established.
These were characterised using short tandem repeat (STR) profiling and genotyped by whole
exome sequencing. Multiple in vitro assays were performed to document their morphology, growth
characteristics, migration and invasion characteristics, and in vivo xenograft growth. Results:
STR profiles of the cSCC lines allow the confirmation of their unique identity. Phylogenetic trees
derived from exome sequence analysis of the matched primary and metastatic lines provide insight
into the genetic basis of disease progression. The results of in vivo and in vitro analyses allow
researchers to select suitable cell lines for specific experimentation. Conclusions: There are few
well-characterised cSCC lines available for widespread preclinical experimentation and drug screening.
The described cSCC cell line panel provides a critical tool for in vitro and in vivo experimentation.
Keywords: squamous cell carcinoma; cutaneous; in vitro; keratinocytes
1. Introduction
Cutaneous squamous cell carcinoma (cSCC) is a common and growing problem, with over
45,000 cases per year in the UK in 2015 [1]. There is a dearth of effective treatment for high-risk and
metastatic disease, which has a high mortality (40% within 3 years), but the advent of immunotherapy
for melanoma has opened up the possibility of treating advanced cSCC with PD1/PD-L1 and CTLA4
targeted immunotherapies [2]. However, targeted therapy remains elusive; cSCC has a very high
mutational burden with the commonest mutated genes being Notch 1 and 2, TP53 and CDKN2A [3,4].
Although the application of new genomics and transcriptomics has been informative in primary
invasive cSCC and precursor lesions, the genetic drivers of metastasis are poorly understood [5].
Testing the functional effects of putative genetic drivers requires robust preclinical testing, as do the
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high throughput screening platforms for drug discovery. A considerable number of keratinocyte
cancer cell lines from head and neck SCC (HNSCC) have been developed over the years [6]. They
have been widely used in in vivo and in vitro modelling to study the biology of HNSCC, although
genotyping has revealed the extent of cross-contamination and mistaken identity of these lines (37/85) [6].
In comparison, few cSCC cell lines have been developed. We report a panel of 16 patient-derived cSCC
lines derived in our laboratory. We clarify and define the nomenclature for these lines, referencing also
their use in previous publications. We describe their genetic characterisation and show that they closely
recapitulate the biology of primary tumours, both in vitro in 2D and 3D culture, and also in vivo in
subcutaneous xenografts, providing a unique resource for preclinical testing.
2. Results
2.1. Case Histories and Histopathology
A total of 16 cell lines were derived from 11 patients with cSCC attending dermatology outpatient
clinics. Five of these 11 patients were immunocompetent individuals (three male and two female)
and six of these 11 patients were immunosuppressed male organ transplant recipients (OTR) aged
51–87 years and 45–67 years, respectively, at the time of biopsy (Table 1). One cell line was derived
from premalignant forehead skin (PM1), 13 of the 16 cell lines were derived from primary cSCC lesions
and two from lymph node metastases. One of the immunosuppressed donors contributed five of
the 16 cell lines: one premalignant, three primary and one metastatic cSCC [7] (Figure 1). One of the
immunocompetent donors (77-year-old male) contributed two lines (IC1 and IC1MET), derived from a
moderately differentiated primary cSCC arising on the right temple and its subsequent metastasis to
the right pre-auricular lymph node (Figure 1). The clinical details, histological classification (from well-
to poorly-differentiated) and immunosuppressive drug details are shown in Table 1. Some of the cell
lines have been developed over the last 30 years [7] but the majority over the last 10 years. There has
been remarkable conservation of findings following passaging. All lines were established by the same
technique as described in the methods section. However, before performing whole exome sequencing
(WES), cell lines were re-derived and full characterisation, including WES, was performed on an
established collection. This collection is now being made widely available, and the publication refers
to this collection only and not to any earlier derivations of the cell lines. The only observed difference
between immunosuppressed and immunocompetent cell lines was the finding of an azathioprine
signature on whole exome sequencing in lines from immunosuppressed patients [3]. None of the
other functional observations, both described in this and previous papers, have segregated cell lines
according to the immune status of the donor (Figure 2, Figure 3, Figure 4 and Table A1).
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Table 1. Details of established cell lines, patient characteristics, immune therapies, histopathological status, and identification of in vivo and in vitro tests.
Cell line Tumour ImmuneStatus
Immune
Therapy 1 Site
SCC
Histology Age Sex
Germline
DNA 2
Organotypic
Invasion
Transwell
Migration
Tumorigenicity
3
PM1 #
pre-malignant
lesion RT A,P scalp dysplastic 45 M
dermal
fibroblasts ND ND 0/10
4, 6/6
MET1 # primary RT A,P
dorsum left
hand MD 45 M
dermal
fibroblasts ND 40–100% 5/10
4, 6/6
MET2 #
recurrence of
MET1 RT A,P
dorsum left
hand MD 45 M
dermal
fibroblasts ND 40–50% 7/10
4
MET4 #
metastasis of
MET 1/2 RT A,P
left axillary
lymph node metastasis 46 M
dermal
fibroblasts ND 40–60% 5/10
4; 6/6
SCC T9 #
unrelated
primary of
MET patient #
RT A,P right hand WD 45 M dermalfibroblasts ND ND ND
SCC IC1 primary IC N/A right temple MD 77 M lymphocytes 30–50% 14/14 5; 6/6
SCC
IC1MET
metastasis of
IC1 IC N/A
right
preauricular
lymph node
metastasis 77 M lymphocytes ND 10–50% 6/6
SCC IC8 primary IC (PUVA) N/A buttock PD 51 F lymphocytes 20–25% ND
SCC IC12 primary IC N/A left calf MD-PD 87 F lymphocytes ND ND ND
SCC IC18 primary IC N/A right ear MD 81 M lymphocytes ND ND ND
SCC IC19 primary IC N/A scalp MD 81 M lymphocytes ND 20–50% ND
SCC T1 primary RT C, P forearm WD 61 M N/A ND 30–50% 0/4 5
SCC T2 primary CT A, C, P hand WD 66 M lymphocytes ND ND 2/3 5
SCC T8 primary RT C, P ear PD 67 M lymphocytes ND ND 3/4 5
SCC T10 primary RT A *, C, P left shin MD 60 M lymphocytes ND ND ND
SCC T11 primary RT A *, C, P back PD 48 M lymphocytes ND ND ND
# all cells derived from the same patient; IC = Immuno-competent, RT = renal transplant, PUVA= psoralen + ultraviolet A, CT = cardiac transplant, ND= not determined; 1 Patients received
imunosuppressive therapy as follows: A, azathioprine; C, Cyclosporine A; M, mycophenolate mofetil (MMF); P, prednisolone; *, patient had stopped treatment by the time of lesional
biopsy; 2 Whole exome sequencing was only performed on those cell lines where germline DNA was available; 3 Proportion of mice (female SCID Balb/c unless otherwise indicated) with
detectable tumours after bolus subcutaneous injection of cells; 4 Data from earlier xenograft experiments performed in male CD1 nu/nu mice using cells at culture passage pp. 8–15
(MET lines) or p > 40 (PM1) (previously published in Proby et al 2000); 5 Data previously published in Watt et al 2011 using cells at culture passage pp. 18–24.
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Figure 1. Clinical presentation. Primary cutaneous squamous cell carcinoma (cSCC) on the temple of 
an immunocompetent male which gave rise to the IC1 cell line (A). Lymph node metastasis which 
gave rise to the IC1MET cell line (B). Local recurrent cSCC on the hand of an immunosuppressed 
male transplant recipient, giving rise to the MET2 cell line (C). 
2.2. In Vitro Characteristics: Cell Morphology, Growth Curves, Transwell Migration and Organotypic 
Invasion 
Cell morphology representative of nine of the 16 lines is shown in Figure 2A. Cells from two 
primary, IC1 and T1, and two metastatic lines, MET4 and IC1MET, were seeded into six multiwell 
plates and growth measured at days 3, 5 and 7 (Figure 2B). All four lines entered into an exponential 
growth phase by 3–5 days in culture. Metastatic cells grew faster than primary cells, irrespective of 
the immune or differentiation status of the tumour from which the cells were derived. These four 
lines, along with cells from two additional primary lines (MET1 and IC19) were treated with 
mitomycin C, to ensure that migration was proliferation‐independent, before being seeded into the 
upper chamber of transwell inserts and migrated for 18 h (Figure 2C). A greater proportion of cells 
from primary lines belonging to the isogenic cell line pairs (MET1/MET4 and IC1/IC1MET), migrated 
compared to their isogenic metastatic counterparts. The remaining primary cell lines IC19 and T1 
migrated to a lesser extent than MET1 but a similar extent to IC1. Cells from the primary lines IC8 
and IC1 were seeded onto collagen/matrigel matrices containing normal human fibroblasts and 
grown for 7 days at 37 °C (Figure 2D). Both lines formed epidermal layers, with IC1 showing greater 
levels of invading cells that invaded deeper into the dermis compared to IC8. The morphology of the 
IC1 keratinocytes shows dysplastic features. 
Figure 1. Clinical presentation. Primary cutaneous squamous cell carcinoma (cSCC) on the temple
of an immunocompetent male which gave rise to the IC1 cell line (A). Lymph node metastasis which
gave rise to the IC1MET cell line (B). Local recurrent cSCC on the hand of an immunosuppressed male
transplant recipient, giving rise to the MET2 cell line (C).
2.2. In Vitro Characteristics: Cell Morphology, Growth Curves, Transwell Migration and Organotypic Invasion
Cell morphology representative of nine of the 16 lines is shown in Figure 2A. Cells from two
primary, IC1 and T1, and two metastatic lines, MET4 and IC1MET, were seeded into six multiwell
plates and growth measured at days 3, 5 and 7 (Figure 2B). All four lines entered into an exponential
growth phase by 3–5 days in culture. Metastatic cells grew faster than primary cells, irrespective of the
immune or differentiation status of the tumour from which the cells were derived. These four lines,
along with cells from two additional primary lines (MET1 and IC19) were treated with mitomycin C,
to ensure that migration was proliferation-independent, before being seeded into the upper chamber
of transwell inserts and migrated for 18 h (Figure 2C). A greater proportion of cells from primary lines
belonging to the isogenic cell line pairs (MET1/MET4 and IC1/IC1MET), migrated compared to their
isogenic metastatic counterparts. The remaining primary cell lines IC19 and T1 migrated to a lesser
extent than MET1 but a similar extent to IC1. Cells from the primary lines IC8 and IC1 were seeded
onto collagen/matrigel matrices containing normal human fibroblasts and grown for 7 days at 37 ◦C
(Figure 2D). Both lines formed epidermal layers, with IC1 showing greater levels of invading cells that
invaded deeper into the dermis compared to IC8. The morphology of the IC1 keratinocytes shows
dysplastic features.
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Figure 2. cSCC cell line characterisation. Phase contrast images demonstrate that the cSCC cell lines 
have distinct morphologies based on the differentiation status of the tumours from which they were 
derived and their metastatic potential (A). The growth rate of two metastatic, MET4 and IC1MET, and 
two primary, IC1 and T1, cSCC lines; two of which were isogenic lines, IC1MET/IC1 (B). Transwell 
migratory potential of a selection of the cSCC lines, including four immunocompetent patient‐derived 
and three immunosuppressed transplant recipient‐derived lines; representing two separate isogenic 
line pairs, IC1/IC1MET and MET1/MET4, alongside three primary lines (C). Organotypic hematoxylin 
and eosin (H&E) images of two immunocompetent cSCC lines, IC8 and IC1. IC1 was derived from a 
tumour that went on to metastasise. Invading cells are shown by arrows (D). Scale bars = 100 μm. 
Values presented as mean ± SEM. Experiments performed twice in triplicate (A–C) and a total of three 
times (D). 
2.3. In Vivo Tumorigenicity 
Fourteen of the 16 cell lines were investigated in xenograft models. The occurrence and growth 
rate of tumours developing after subcutaneous injection varied between cell lines (Table 1, Figure 
3A). Palpable tumours developed in 100% of severe combined immune deficiency (SCID) mice 
injected with IC1, IC1MET, MET1, MET4, PM1 within the first 2 weeks of injection, with some intra‐
tumoural growth variability observed. PM1 cells established tumours which maintained a stable 
Figure 2. cSCC cell line characterisation. Phase contrast images demonstrate that the cSCC cell lines
have distinct morphologies based on the differentiation status of the tumours from which they were
derived a d their metastatic potential (A). The growth r e of two metastatic, MET4 and IC1MET, and
two primary, IC1 and T1, cSCC l nes; two of which were isogenic lines, IC1MET/I 1 (B). Transwell
migratory potential of a selection of the cSCC lines, including four immunocompetent patient-derived
and three immunosuppressed transplant recipie t-derived lines; representing two s parate isogenic
line pairs, IC1/IC1MET and MET1/MET4, alongsi e three primary lines (C). Organotypic hematoxylin
and eosin (H&E) images of two immunocompetent cSCC lines, IC8 and IC1. IC1 was derived from
a tumour that went on to metastasise. Invading cells are shown by arrows (D). Scale bars = 100 µm.
Values presented as mean ± SEM. Experiments performed twice in triplicate (A–C) and a total of three
times (D).
2.3. In Vivo Tumorigenicity
Fourteen of the 16 cell lines were investigated in xenograft models. The occurrence and growth
rate of tumours developing after subcutaneous injection varied between cell lines (Table 1, Figure 3A).
Palpable tumours developed in 100% of severe combined immune deficiency (SCID) mice injected with
IC1, IC1MET, MET1, MET4, PM1 within the first 2 weeks of injection, with some intra-tumoural growth
variability observed. PM1 cells established tumours which maintained a stable volume for 10 weeks
when they were harvested (Figure 3A). MET1 and MET4 tumours grew with some variability, and
several tumours were harvested upon ulceration. IC1 tumours grew rapidly but some regression was
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seen between 2–4 weeks post-injection, prior to further tumour growth and then variable subsequent
regression after 6 weeks (Figure 3A and data not shown)—suggesting that IC1 xenografts could be a
suitable choice as short-term drug testing models. IC1MET tumours grew with consistent kinetics and
could be a suitable model for longer-term drug testing. The histology of the xenograft recapitulated
the pathology of the original tumours, with ulceration apparent in PM1 xenografts (Figure 3B).
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2.4. Genetic Analyses
2.4.1. Short Tandem Repeat (STR) DNA Profiling
Fifteen STR loci plus amelogenin were genotyped to give tumour-specific profiles (Table 2). These
profiles authenticated all cell lines as human and were unique to the patient of origin and distinct from
previously published human cell line profiles in the American Type Culture Collection (ATCC) STR
database. For the two isogenic line sets IC1/IC1MET and MET1/MET2/MET4, tumour recurrences
or metastases demonstrated STR profiles identical to the primary tumour. In contrast, two isogenic
lines (PM1 and T9) belonging to the latter isogenic set (MET series) but derived from separate primary
lesion sites demonstrated highly similar but non-identical profiles which could be distinguished from
the MET lines by their genotype at the CSF1PO, D3S1358 and TH01 loci.
2.4.2. The Genomic Landscape of Cell Lines
Whole exome sequencing (WES) was performed on the 15 lines, for which matched normal
samples were available (GSE98780) [3]. Our results suggested that mutational profiles, e.g., somatic
mutations and copy number alterations (CNA) of cSCC lines, were comparable with those of the patient
tumour sample set, properly reflecting the complexity of the disease. Genomic abnormalities observed
in cell lines include mutations in many reported cSCC drivers, such as TP53, NOTCH1/2, CDKN2A,
HRAS, SF3B1 and PTEN, as well as novel drivers, including ATP1A1 and GRHL2 [3]. The molecular
profiling of these lines provides a unique valuable resource for studying the functional significance of
novel molecular events responsible for cSCC development and progression.
2.4.3. Phylogenetic Analysis of Isogenic Lines
The non-silent mutations identified were used to construct evolutionary trees for the two
isogenic cell line sets, primary cSCC IC1 and its metastasis IC1MET, as well as for the three related
(MET1/MET2/MET4) and two unrelated lines (PM1/T9) derived from the single immunosuppressed
transplant recipient male patient (Figure 4A). A majority (86% and 60% for the IC1 and MET trees,
respectively) of all non-synonymous mutations identified in the related lines were truncal (early),
reflecting the clonal similarity between metastatic and primary lines (Figure 4A). For late branch
mutations, most of them occurred in the metastatic branch, not the primary specific lines (87% and
82% for the IC1 and MET trees, respectively). All mutations in the known drivers (TP53, NOTCH1/2
and CDKN2A) appeared to be truncal, highlighting their significance in initiating and establishing
the dominant clones (Figure 4A). We next looked for genomic events that could potentially drive
and/or contribute to metastatic progression. Based on the phylogenetic analysis, we identified 58
commonly mutated genes between IC1MET and MET4 metastasis-specific branches, which were not
mutated in any of the primary lines. Gene-set enrichment analysis using Database for Annotation,
Visualization and Integrated Discovery (DAVID) Bioinformatics resources revealed that gene
ontology (GO) biological processes, such as the regulation of transcription (fold enrichment, FE = 2.43;
false discovery rate (FDR) = 9.68 × 10−4), chromatin modification (FE = 6.58, FDR = 2.72 × 10−2), RNA
splicing (FE = 6.35, FDR = 3.17 × 10−2), and the mRNA metabolic process (FE = 4.87, FDR = 0.09),
were significantly overrepresented for these 58 genes, highlighting the potential involvement of these
pathways and processes in driving or significantly contributing to cSCC metastasis.
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Table 2. Summary of short tandem repeat (STR) genotyping gives a characteristic genotype for the identification of individual cell lines.
Cell Line AMEL CSF1PO D13S317 D16S539 D18S51 D19S433 D21S11 D2S1338 D3S1358 D5S818 D7S820 D8S1179 FGA TH01 TPOX vWA
SCC IC1 X, Y 12, 14 9, 13 9, 13 15, 17 15, 16.2 29, 30 19, 25 14, 17 11, 13 8, 11 13, 13 21, 24 9.3, 9.3 8, 8 16, 16
SCC IC1MET X, Y 12, 14 9, 13 9, 13 15, 17 15, 16.2 29, 30 19, 25 14, 17 11, 13 8, 11 13, 13 21, 24 9.3, 9.3 8, 8 16, 16
PM1 X, Y 9, 13 8, 12 11, 13 18, 19 14, 14 30.2, 33.2 17, 21 14, 14 11, 12 7, 8 12, 15 24, 24 8, 9.3 9, 11 18, 19
MET1 X, Y 13, 13 8, 12 11, 13 18, 19 14, 14 30.2, 33.2 17, 21 16, 16 11, 12 7, 8 12, 15 24, 24 9.3, 9.3 9, 11 18, 19
MET2 X, Y 13, 13 8, 12 11, 13 18, 19 14, 14 30.2, 33.2 17, 21 16, 16 11, 12 7, 8 12, 15 24, 24 9.3, 9.3 9, 11 18, 19
MET4 X, Y 13, 13 8, 12 11, 13 18, 19 14, 14 30.2, 33.2 17, 21 16, 16 11, 12 7, 8 12, 15 24, 24 9.3, 9.3 9, 11 18, 19
SCC T9 X, Y 9, 13 8, 12 11, 13 18, 19 14, 14 30.2, 33.2 17, 21 14, 16 11, 12 7, 8 12, 15 24, 24 8, 9.3 9, 11 18, 19
SCC IC8 X, X 12, 13 11, 11 11, 12 13, 18 13.1, 14 29, 29 17, 21 16, 16 13, 13 8, 12 16, 16 19, 23 9, 9 8, 8 15, 16
SCC IC12 X, X 12, 12 11, 12 12, 13 15, 16 13.1, 14 28, 31.2 17, 17 15, 15 12, 13 10, 11 11, 12 22, 24 6, 10 10, 11 17, 19
SCC IC18 X, X 11, 11 10, 11 9, 13 12, 12 13.1, 15 28, 32.2 17, 18 16, 17 13, 13 9, 11 8, 12 21, 21 6, 8 9, 9 14, 17
SCC IC19 X, X 11, 11 10, 12 9, 12 11, 18 13.1, 15.2 32.2, 32.2 19, 21 15, 15 12, 12 9, 12 13, 15 20, 22 6, 7 11, 11 16, 17
SCC T1 X, Y 12, 12 9, 12 12, 13 12, 14 14, 15 30, 32.2 18, 20 17, 17 12, 13 9, 10 13, 13 21, 24 9, 9.3 9, 12 14, 16
SCC T2 X, Y 10, 10 11, 14 10, 11 12, 13 14, 16 28, 31 17, 20 15, 15 11, 12 ND 13, 15 22, 22 6, 6 8, 9 15, 18
SCC T8 X, X 10, 10 13, 13 11, 12 12, 13 14, 15 31.2, 32.2 25, 25 14, 15 12, 12 11, 12 13, 13 21, 23 8, 8 11, 11 14, 19
SCC T10 X, Y 10, 11 8, 9 9, 10 13, 19 15, 15 29, 30 22, 24 16, 17 11, 11 ND 10, 15 24, 25 9, 9 8, 11 14, 17
SCC T11 X, Y 10, 12 11, 12 12, 13 11, 13 12, 14 29, 30 17, 19 14, 16 11, 11 7, 12 11, 15 19, 20 6, 9.3 8, 8 18, 18
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Figure 4. Phylogenetic analysis and mutational signatures of tw is ic cell line series. The numbers
of non-synonymous truncal and branch mutations are indicated (A). A significant (p < 0.0001) decrease
in C > T transitions accompanied by a significant (p < 0.0001) increase in A > G transitions was observed
during the evolution of both tumour series (B). IC1/IC1MET, paired primary and metastatic cSCC from
an immunocompetent indivi ual; MET1/MET2/MET4, c ll lines de ived fro a primary cSCC and its
recurrence a d metastasis, respectively, from an immu osuppressed organ transplant recipient; PM1,
premalignant cell line generated from dysplastic skin from the same patient; T9, cell line generated
from a distinct primary cSCC from the same patient.
We next investigated the mutational signatures (with respect to transiti ns a transversions) for
early and late utations, and aimed to identify any significant diff ences between them. As shown in
Figure 4B, a significantly higher proportion of C > T/G > A transitions (often induced by UV damage)
was observed in truncal mutations (80%) compared to their branch counterparts (40%, Fisher’s exact
test, p < 0.0001). In co trast, the proportion of other mutations became less abundant. In particular,
there was a >10-fold increase in A > G/T > C transitions during the tumour progression, representing
more than 20% of all late mutations for both series (Figure 4B). This suggests that signatures 5,
12 and 16 (see https://cancer.sanger.ac.uk/cosmic/signatures), which often consist of A > G/T > C
substitutions, became more dominant after the tumours are fully established and during the tumour
progression. Although signature 7 (UV light exposure) remained the most dominant signature
throughout, its influence became important after the full establishment and during the progression
and metastatic stages.
2.4.4. Genome-Wide Methylation Profiling of cSCC Cell Lines
We then explored the methylation characteristics of six cSCC cell lines (T1, T2, IC1, T8, MET1,
MET2) using genome-wide DNA methylation microarray. The cSCC lines were hybridised to the same
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chip with three normal human keratinocytes (NHK) to account for possible batch effects. Genome-wide
methylation profiles reflected the original histologies (cSCC vs. NHK) and also differentiation status
subtypes of cSCC based on Pearson’s correlation (Figure 5). Cell lines derived from poorly differentiated
tumours formed a cluster, while cell lines derived from well- and moderately-differentiated cSCC
(T1, T2, IC1) formed a separate cluster. A comparison of genome-wide methylation profiles of NHK and
cSCC cell lines revealed a statistically significant difference in methylation in 361 unique genes (adjusted
p-value ≤ 0.01), including known cancer drivers (MAP2K2, WNT5A, COL4A1, BMP2 and FGF7).
We then explored the potential enrichment of subsets of differentially methylated genes. Gene-set
enrichment analysis revealed significant enrichment in several canonical pathways including MAPK,
JAK-STAT, insulin signaling and the p53 pathway. P53 is known to play a critical role in cSCC
oncogenesis, and genes involved in p53 signaling, IGF1, IGFBP3, CASP8, SERPINB5, were identified
as being differentially methylated. This suggests that the genome-wide methylation profile retained by
stable cell lines maintains the original tissue features and reflects the methylation changes in processes
inherent to cSCC onset and progression.
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Figure 5. Heatmap of Pearson’s correlation of genome-wide methylation profiling of six cSCC cell
lines and three normal human keratinocytes (NHK). NHK (green) cluster together separately from
cSCC, poorly-differentiated cSCC (purple) form a cluster with the two isogenic cell lines—MET1 and
MET2—forming a tight subcluster. Two well-differentiated cell lines (T1 and T2, light blue) formed a
cluster with a moderately-differentiated cell line, IC1 (dark blue).
3. Discussion
We describe for the first time a unique panel of 16 cSCC lines which have been extensively
characterised in terms of clinical and histological phenotyping; genotyping by STR DNA profiling,
exomic sequencing, copy number alteration analysis and phylogenetic analysis; in vitro cell morphology,
growth, transwell migration, organotypic invasion; and in vivo tumourigenicity. This panel includes
multiple isogenic lines and lines which represent the spectrum of tissue sites and histologies, and is a
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unique resource for preclinical cSCC research. Indeed, to date, a few of these lines have been used
individually in multiple collaborative research efforts (Table A1).
3.1. Existing cSCC Cell Lines
There are few well-established cSCC cell lines. An online search using the cell line catalogue
databases ATCC, the European Collection of Authenticated Cell Cultures (ECACC) and the German
Collection of Microorganisms and Cell Cultures GmbH (DSMZ) revealed that the only SCC lines listed
are of head and neck origin. As far as we are aware, the only cutaneous SCC line widely available
commercially is A431. This line is of vulval origin [8–10] and, although there is no evidence of human
papillomavirus (HPV) involvement, it is unlikely to reflect the mutational profile of UV-associated
cSCC [3]. The panel of HNSCC lines developed by Rheinwald and Beckett in 1980 [11] included cell
lines (SCC12, SCC13) which derived from a cutaneous SCC: clinical details of the site and tumour
characteristics are not available, although these lines have been widely used experimentally [12]. There
are a number of publications using the UT-SCC HNSCC lines, which include five primary cSCC lines
(UT-SCC-12A, 91, 105, 111, 118) and three metastatic cSCC lines (UT-SCC-7, 59A, 115) [13–15], but the
characterisation of these lines has not been reported comprehensively. SRB-1 and SRB-12 cell lines
were derived from a moderately well-differentiated cSCC [6,16,17], and Colo16 was developed from a
metastatic cSCC arising in a chronic burn scar on the leg of a 59-year-old black female [18]; all three
have subsequently been used in drug discovery studies [19–27]. A model of skin carcinogenesis
has been developed using mutant Ras/Cdk4 transfection of normal keratinocytes [28,29]; however,
HRas mutations are uncommon in human cSCC. HaCaT cells were spontaneously immortalised from
clinically normal peritumoural tissue and are widely used as immortalised keratinocytes as they closely
resemble normal keratinocytes in their growth and differentiation potential [30]. The parent line is
non-tumorigenic through multiple passages (320), but malignant subclones have been developed
following transfection with mutated val-12 Harvey Ras oncogene [31]. Our panel therefore constitutes
the largest panel of patient-derived cSCC cell lines and is the most comprehensively characterised.
3.2. Tumour Microenvironment
Cancer-derived cell lines lack the critical influence in vivo from the tumour microenvironment, but
this can be mimicked in organotypical cultures and subcutaneous xenografts. We present the optimal
lines from our series, which produce early xenografts and highlight the range of individual tumours from
multiple mice in each of the key lines. This illustrates that the optimal line for consistent rapid tumour
growth for drug and therapeutic screening appears to be IC1MET. The remarkable conservation of the
pathological changes found in the primary tumours is shown in the photomicrographs. Particularly
striking are the hyperkeratotic lesions from a field of actinic dysplasia (hence PM—premalignant).
As the xenografts are in SCID mice, this clearly provides a permissive environment for tumour
development, which allows the intrinsic pattern of tumour differentiation to develop. However, in
our published studies of organotypical cultures using keratinocytes and fibroblasts from patients who
develop cSCC due to the rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB-type
VII collagen deficiency), RDEB cancer-associated fibroblasts (CAFs) increased the adhesion and
invasion of both tumour (including IC1) and non-tumour keratinocytes [32]. It would therefore be
of interest to develop xenografts incorporating components of the tumour microenvironment (TME)
such as CAFs, and also in mice with immune reconstitution using human immune cells in future
experiments. Current xenograft models would be more suitable for testing targeted therapies rather
than immune modulators.
3.3. Characterisation of cSCC Cell Lines for Future Experimentation
There have been a number of potential problems in the use of cSCC cell lines derived from tissue
collections or by multiple partnering labs using those cell lines for experimentation. For example,
analysis of 122 HNSCC lines (including three cSCC lines SRB1, SRB12, Colo16) authenticated only
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85 unique cell lines by STR DNA profiling within this collection and highlighted misidentification
and cross-contamination as common problems [6]. Details of STR DNA profiling of our cSCC cell
line panel authenticated against the primary tumour of origin has therefore been presented here in
order to provide researchers with an efficient method of verifying our cell lines [6]. Additionally,
the morphology of the cell lines and the expected growth curves have been included for the assistance
of new users (Figure 2).
3.4. Methylation Profiling
Perturbations in epigenetic regulation have been associated with the oncogenic process across a
number of tumours, and many currently used anti-cancer medications target an epigenetic mechanism,
such as DNA methylation inhibitors. DNA methylation profiling of cancer cell lines, often paired
with methylation profiling of additional tissue samples, represents a method for identifying potential
targets of pharmacological targeting and gaining further insight into tumour biology.
Our cell lines harbor epigenetic marks with biological functions linked to cSCC tumourigenesis,
such as hypomethylation of RUNX1, the activation of which is linked to SCC formation in mice [33].
WNT5A associated with cSCC invasiveness was also hypomethylated in cSCC cell lines [34]. Tumour
suppressor TP53 promoter was previously shown to be hypermethylated in cSCC, and we detected
CpG hypermethylation of tumour protein p53 inducible protein 3, which is involved in p53-mediated
cell death.
An unsupervised clustering analysis of genome-wide methylation data was able to distinguish
cSCC-derived cell lines from cultured NHK and to separate cSCC cell lines based on the histology of
the original tumour, with isogenic cell lines clustering closely together. Taken together, this shows that
cultured cSCC cell lines maintain key epigenetic characteristics concordant with the original phenotype
and retain certain critical epigenetic alterations inherent to the process of cSCC oncogenesis, and that
cSCC lines may be utilised for rapid screening and identification of novel epigenetic marks and targets
in cSCC.
3.5. Application of cSCC Cell Lines in Drug Screening
Cancer-derived cell lines have been widely used to develop anti-cancer drugs by high throughput
screening and predictive modelling [35,36]. Although they tend to be developed from aggressive
tumours and are therefore imperfect models alone for drug discovery programmes, they are not
limited by resource or tumour size, a significant factor when using cSCC for patient-derived xenografts.
Screening of the proteasome inhibitors bortezomib, ixazomib and carfilzomib, and ubiquitin inhibitors
has been performed on normal keratinocytes and eight cSCC lines including IC1, IC1MET, MET1
and MET4 by assessing the effects on cell viability and cell death of long and short exposure to these
clinically approved drugs. There were variations in cell line sensitivity/resistance [37]. Following an
siRNA screen which identified the spliceosome as a potential target for cSCC therapy, small molecule
inhibitors of the spliceosome targeting the splicing factor SF3B1/SF3b155 have also been studied on our
cell lines (IC1, IC1MET, IC8, IC12, IC18, MET1 and MET4). They are more sensitive to pladienolide
B than normal cells [38]. The effects of mitogen-activated protein kinase kinase (MEK) inhibition on
cSCC responses were tested using two MEK inhibitors, trametinib and cobimetinib, in 10 cell lines
(including IC1, T2, T3, T8), nine of which responded at high concentrations. However, this sensitivity
was not correlated with the mutational status of RAS or epidermal growth factor receptor (EGFR) [27].
3.6. The Preclinical Pipeline
Animal models have been widely used to study skin carcinogenesis. Chemical carcinogenesis
induced by tumour initiator and promotor-DMBA/TPA treatment has been the basis of a widely studied
animal model of cSCC. These tumours differ from human disease as they develop predominantly
papillomatous lesions. Although they have similar driver gene mutations in, for example NOTCH 1
and 2 [39], they bear much higher levels of HRAS mutation. In patients, lesions tend to progress from
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normal skin to premalignant actinic keratoses bearing dysplastic keratinocytes, through to invasive
tumours. This morphology is better modelled in the solar-simulated ultraviolet radiation (SSUV) mouse,
where chronic UV exposure of hairless mice produces keratotic lesions, which are phenotypically and
genetically closer to the human tumours [40]. However, this requires very prolonged UV exposure,
which limits the numbers of animals available. We have therefore developed a preclinical pipeline,
which we believe has the power to identify relevant human carcinogenic pathways (Figure 6). Key to
this is our human cSCC cell line panel used in organotypical cultures, together with subcutaneous and
surface xenografts. We then confirm the findings in engineered mouse models as proof of principle
for the human studies, as described in our publication on the role of TGFbeta receptors in squamous
carcinogenesis [41].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 15 of 27 
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3.7. Models for Metastasis
Key to understanding the high risk of metastasis of cSCC in OTRs [42] has been the ability to develop
paired cell lines from both primary cSCC and lymph node metastasis, in both immunocompetent
(IC1, IC1MET) and immunosuppressed (MET1/MET4) individuals [43]. By analyzing WES mutational
data associated with branching from trunk to metastasis, we have constructed a phylogenetic tree
(Figure 4), and this will be a starting point for further investigating key drivers of cSCC progression.
There are few models of cSCC metastasis, but these cell lines could be used to screen for agents targeting
metastatic disease. Regulatory requirements mandate that the animals bearing tumour xenografts
have to be sacrificed once tumours reach a certain size, often before metastases can develop. However,
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this may be circumvented by systemic administration of tumour cells or by removing the primary
tumour. These cSCC cell lines will be important for developing new models of metastasis.
4. Materials and Methods
4.1. Patient Samples
Clinically diagnosed cutaneous SCC lesions were surgically removed from patients attending
dermatology clinics at our institution. Histopathologic diagnosis of all samples was confirmed by an
experienced dermatopathologist. A 4–6 mm punch biopsy was placed into collection media comprising
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies Ltd., Paisley, UK) supplemented with
5% fetal bovine serum (FBS, Biosera, Ringmer, UK), 100 units/mL penicillin, 100 µg/mL streptomycin
and 2.5 µg/mL amphotericin B (all Life Technologies Ltd., Paisley, UK). Venous blood samples were
drawn into ethylenediaminetetraacetic acid (EDTA) tubes, aliquoted into cryovials and stored at −80 ◦C.
Ethical approval (REC Reference 08/S1401/69, 05 November 2008) for this study was obtained from the
East London and City Health Authority local ethics committee and the study was conducted according
to the Declaration of Helsinki Principles. All patients participating in the study provided written,
informed consent.
4.2. Establishment of cSCC Cell Lines
Cell lines were established from cutaneous SCC tissue as described in Purdie et al. 2011 [44].
In brief, tumour biopsies were washed in PBS followed by 1 × versene (EDTA, Life Technologies
Ltd., Paisley, UK) and transferred to a Petri dish containing 0.25% trypsin (Life Technologies Ltd.,
Paisley, UK) and then cut into small fragments 1–2 mm in size and incubated at 37 ◦C for an hour with
intermittent agitation. The tissue was dissociated with needles and the suspension mixed with an
equal volume DMEM supplemented with 10% FBS and passed through a 100 µm cell strainer. Cells
were recovered by centrifugation, washed with PBS, resuspended in keratinocyte medium (a 3:1 V/V
mixture of DMEM and Ham’s F12 (Life Technologies Ltd., Paisley, UK) supplemented with 10% FBS
and a cocktail of mitogens: 0.4 µg/mL hydrocortisone, 10–10 M choleratoxin, 5 µg/mL transferrin,
2 × 10–11 M liothyronine, 5 µg/mL insulin, 10 ng/mL epidermal growth factor (EGF); all mitogens
from Sigma-Aldrich, Poole, UK with the exception of cholera enterotoxin from Enzo Life Sciences
Ltd., Exeter, UK and mouse EGF from AbD Serotec, Oxford, UK) and plated into a flask pre-seeded
with mitotically inactivated Swiss 3T3 fibroblast feeder cells. Cultures were grown at 37 ◦C in 10%
CO2. Upon reaching 80% confluence, cells were detached from the flask with trypsin/EDTA, washed
in PBS and re-seeded at a 1:3 ratio. Cultures that had not senesced after 10 passages were considered
to display extended lifespan and met the criteria for inclusion in this study.
4.3. 3-D Organotypic Cultures
Collagen/Matrigel gels were prepared by mixing on ice 3.5 volumes of collagen type I (Marathon
Laboratory Supplies, London, UK) with 3.5 volumes of Matrigel® (Becton-Dickinson, Oxford, UK),
1 volume 10× MEM and 1 volume FBS. The solution was equilibrated with 1 M NaOH and 1 volume
DMEM/10% FBS containing normal human fibroblasts (NHF) at a concentration of 2 × 106/mL added.
Polyethylene terephthalate 0.4 µm inserts (Sarstedt, Leicester, UK) were placed into 24-well plates
before 200 µL of the gel solution was added to each and left for 1 h at 37 ◦C and 5% CO2 to polymerise.
Keratinocyte cells, in a media volume of 200 µL per well, were added at a density of 1 × 106/mL.
The cell suspension was added to the top of the gel and 400 µL of medium was added to the bottom
of the well. Inserts were incubated at 37 ◦C at 5% CO2 for 24 h. After overnight incubation, the gels
were lifted on steel grids with sufficient keratinocyte medium added to reach the undersurface of the
gel and permit the epithelial layer to grow at the air–liquid interface. The gels were harvested after
7 days, fixed in paraformaldehyde and embedded in paraffin. Invasion was assessed by microscopic
examination of 4 µm sections stained with hematoxylin and eosin (H&E).
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4.4. Growth Curve and Cell Migration Assay
Cells were imaged and seeded for growth and migration assays at passages(p)27–28 for MET1
and MET4, p25 for IC8, p18–20 for IC18, MET2, IC1 and IC19, p15–16 for PM1 and T2, p11–12 for T1,
T2, T10, T11 and IC1MET. Cells were seeded in 6-well plates at a density of 8 × 104/well in keratinocyte
medium at 37 ◦C. Cells were dissociated using 0.05% trypsin (Life Technologies Ltd., Paisley, UK) and
counted on days 3, 5 and 7 post-seeding. A Transwell® system incorporating a polycarbonate filter
membrane (6.5 mm diameter, 8 µm pore size; Corning, Sigma-Aldrich, Poole, UK) was used to assess
the rate of cell migration. Mitomycin C-treated keratinocytes (1 × 105) were suspended in 100 µl of 0.1%
bovine serum albumin (BSA) in DMEM/HamF12 (3:1 v/v) medium and seeded in the upper chamber of
the Transwell® insert. The lower chamber was filled with 600 µl of keratinocyte medium. Following
18 h of incubation at 37 ◦C, non-migrating cells on the upper surface of the filter were removed using a
cotton swab. Cells that had migrated to the lower surface of the filter were stained with 1% Borax and
1% methylene blue before being lysed with a solution of 1% sodium dodecyl sulfate (SDS). Migration
rate was determined by calculating the absorbance at 630 nm of the migrating cells as a proportion
of the absorbance of the total number of cells seeded. The experiment was performed in triplicate a
minimum of 2 times.
4.5. In Vivo Xenograft Experiments
Female SCID Balb/c mice or male CD1 nu/nu mice were subcutaneously injected in the right
flank with 4 × 106 or 5 × 106 tumour cells respectively mixed with high-concentration Matrigel®
(Becton-Dickinson, Oxford, UK). Tumour volumes were measured twice a week with a caliper and
calculated using the formula V = pi4/3[(L + W)/4]3, where L is length and W is width. The time points
which ended tumour sampling were determined by the point at which the tumours reached the size
requiring sacrifice of the animal (800 mm3) or developed ulceration.
4.6. DNA Extraction and STR Profiling Analysis
DNA was extracted from cultured cells and blood using the Qiagen DNA Mini kit (Qiagen,
Crawley, UK) according to the manufacturer’s instructions. Quantitation was performed using the
double-stranded DNA-specific Qubit dsDNA BR assay kit in conjunction with the Qubit 2.0 fluorometer
(both Life Technologies Ltd., Paisley, UK). Short tandem repeat (STR) genotyping was performed to
authenticate the unique identity of each cell line. Sixteen loci distributed across the human genome were
amplified using the AmpFLSTR Identifiler PCR Amplification Kit followed by capillary sequencing
on the 3730xl DNA Analyzer (all reagents from Life Technologies Ltd., Paisley, UK). For SNP 6.0
analysis, DNA samples from cultured cells and paired non-tumour blood samples were hybridised to
the microarrays according to the manufacturer’s protocols (Affymetrix, High Wycombe, UK). Exome
sequencing was performed by Oxford Gene Technology (OGT), using Agilent SureSelect All Exon
v5 (Agilent Technologies LDA UK Ltd, Cheshire, UK) for exome capture. Briefly, 1 µg DNA from
each sample was used to prepare the sequencing library through shearing of the DNA followed
by ligation of sequencing adaptors. Sequencing was performed on the Illumina HiSeq platform
(Illumina, Inc., San Diego, CA, USA). Paired-end sequencing (2 × 100 bp) was carried out using HiSeq
sequencing instruments.
4.7. Whole Exome Sequencing (WES) Data Processing and Analysis
The WES data generation and full analytical procedure has been described previously in detail
(accession number GSE98780) [3].
4.8. Copy Number Analysis
Two independent approaches were applied to the copy number analysis of WES data. First,
to generate single nucleotide polymorphism (SNP) and indel variant genotyping information,
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the tumour-normal pair was processed against the reference genome using the VarScan2 germline
variants calling method. The minimum coverage for identified sites was 10 reads for both tumour and
normal. Next, the logR and BAF (B-allele frequency) files were created based on the tumour-normal pair
genotyping information, with the depth information normalised by dividing the depth of each variant by
the median depth across all variants. The ASCAT R package [45] was then used to perform allele-specific
copy number analysis to identify copy number alterations (CNA) and loss-of-heterozygosity (LOH)
regions. The second approach was based on the numbers of reads aligned to each exon between the
tumour and normal pair. VarScan2 copy number calling method was firstly applied. Raw copy number
calls were adjusted for bases guanine and cytosine (GC) content and re-centred to 0 based on the modal
logR value determined by kernel density estimates. Outliers were identified and adjusted using the
data winsorsing procedure. The DNAcopy R Bioconductor package was then employed to identify
joint segments of logR values using the circular binary segmentation (CBS) algorithm [46]. For SNP 6.0
microarray data, copy number analysis was performed using the aroma.affymetrix R package [47].
First, the CRMA v2 algorithm [48] was used for data pre-processing, normalisation and allele-specific
copy number estimates. Paired parent-specific circular binary segmentation (Paired PSCBS) [49] was
further performed on the tumour-normal pair to derive somatic CNAs and decrease-of-heterozygosity
(DH). The ASCAT R package was also used for comparison purposes.
4.9. Phylogenetic Analysis
For two patients where multiple tumour cell lines were generated and sequenced, evolutionary
trees were constructed on the basis of distance matrix among normal control and multiple cell
line samples, using the neighbour-joining algorithm [50] implemented in the PHYLIP package
(http://evolution.genetics.washington.edu/phylip.html). The non-silent mutations were used for this
analysis. The mutations in the tree trunk were defined as “early” events, and the mutations in the
branches after the tree split were “late” events.
4.10. Genome-Wide Methylation Profiling
A total of 6 cSCC lines characterised within this manuscript were used for the detection of
differentially methylated genes. Three early-passage primary normal human keratinocytes derived
from 3 different participants served as a normal control for comparison. DNA was extracted as
described above and bisulfite modification was carried out as the following: 500–1000 ng of DNA yield
from each sample was modified with bisulfite using the EZ DNA Methylation Kit (Zymo, Research,
CA, USA) according to the manufacturer’s instructions. Methylation detection was performed using
the Illumina Infinium HumanMethylation27 BeadChip. This platform detects the methylation status
of 27,578 CpG sites spread across 14,495 genes by sequencing-based genotyping of bisulfite-converted
DNA. Eventual methylation scores (denoted “beta-value”) were generated for each site with BeadStudio
software (Illumina, Inc., San Diego, CA, USA) and raw background-corrected values were used for
further analysis. The methylation assay was performed according to the manufacturer’s instructions.
Briefly, bisulfite-converted DNA was amplified, fragmented and hybridised to the chip arrays, followed
by imaging with the Illumina BeadArray reader. Image processing and intensity data extraction were
performed according to Illumina’s instructions. All analyses were carried out using Bioconductor
and R.
5. Conclusions
We present a definitive analysis of a unique set of cSCC lines that can be used as a model of
skin squamous carcinogenesis for in vivo and in vitro studies. We provide details of their extensive
characterisation, including clinical, phenotypic, genotypic, in vitro and in vivo properties. In addition
to the research reported to date using these cell lines, we anticipate that this unique resource will
continue to provide researchers with a powerful preclinical model for future investigations of the
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molecular drivers of cSCC progression, the identification of novel therapeutic targets and, ultimately,
the development of more effective treatment strategies for this common skin cancer.
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Abbreviations
cSCC cutaneous squamous cell carcinoma
OTR organ transplant recipients
SCID severe combined immune deficiency
STR short tandem repeat
HNSCC head and neck squamous cell carcinoma
ATCC American Type Culture Collection
WES whole exome sequencing
CNA copy number alterations
DAVID Database for Annotation, Visualization and Integrated Discovery
FDR False discovery rate
NHK normal human keratinocyte
ECACC European Collection of Authenticated Cell Cultures
DSMZ German Collection of Microorganisms and Cell Cultures GmbH
HPV human papillomavirus
CAFs cancer-associated fibroblasts
RDEB recessive dystrophic epidermolysis bullosa
TME tumour microenvironment
MEK mitogen-activated protein kinase kinase
EGFR epidermal growth factor receptor
SSUV solar-simulated ultraviolet radiation
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
H&E hematoxylin and eosin
BSA bovine serum albumin
SDS sodium dodecyl sulfate
NHF normal human fibroblasts
SNP single nucleotide polymorphism
LOH loss of heterozygosity
CBS circular binary segmentation
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Appendix A
Table A1. Summary of previous publications using recently fully characterised cSCC lines.
Reference Cell Lines Utilised (Nomenclature Changes)[N.B. SCC Prefix Sometimes Included] Experimental Overview
[7] PM1, MET1, MET2, MET4
PM1 and additional isogenic premalignant cells retain features of normal keratinocytes compared to
MET1-4 cells, which displayed reduced growth requirements, abnormal differentiation, aberrant K18
expression and tumorigenicity in vivo. HPV is not necessary for immortal phenotype maintenance.
[43] MET1, MET2, MET3, MET4 Genetic analysis of MET series.
[51] PM1, MET1, MET4 The oncogenic receptor tyrosine kinase Axl plays a role in driving cSCC; it is upregulated in MET1 andMET4 compared to PM1.
[52] MET1, SCCIC1
Type VII collagen knockdown increases cell migration and invasion in MET1 and SCCIC1 cells.
Knockdown also leads to the disorganisation of epithelial differentiation and the promotion of epithelial to
mesenchymal transition.
[53] MET1, MET4 The flavonoid luteolin inhibited UVB-induced inflammation and apoptosis in normal humankeratinocytes. Exposure to luteolin did not increase cSCC line UVB resistance.
[54] PM1, MET1, MET4 Sensitisation of cSCC cells to cisplatin-induced cell death is achieved by the induction of apoptosis afterAkt inhibition and can be increased with an Akt- and autophagy-inhibitor combination.
[55] PM1, MET1
The activated DNA damage response protein kinase ATM (pATM) is located in the perinucleus and,
focally, in the cytoplasm of PM1 and MET1 cSCC cells. UVB-irradiation resulted in a degree of nuclear
localisation in premalignant PM1 but not MET1 cells. DNA damage response proteins are upregulated in
early carcinogenesis.
[56] MET1, SCCIC1
Axl knockdown in MET1 sensitises cells to UV-induced apoptosis via increased activation of pro-apoptotic
protein Bad, altered conformation of pro-apoptotic proteins Bax and Bak, cytosolic cytochrome c release
and caspase activation. Expression levels upon Axl knockdown were confirmed in SCCIC1 cells.
UV-induced apoptosis was via the mitochondrial-mediated pathway. Axl confers cSCC resistance to
apoptosis.
[57] SCCT1, SCCT2, SCCT8, SCCIC1, SCCIC8,SCCIC12
NOTCH1 and NOTCH2 mutations found in ~75% of cSCCs lines illustrating central roles in the
disruption of microenvironmental communication in cSCC progression.
[58] SCCT1, SCCT2, SCCT8, SCCIC1 The overexpressed cSCC tumour cell-survival genes, PLK1 and C20orf20, when inhibited bysiRNA-mediated knockdown, induced apoptosis in vitro and tumour growth reduction in vivo.
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Table A1. Cont.
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[59] MET1, MET4
The retinoid signalling molecule TRIM16 is reduced during progression from normal to actinic keratosis
and cSCC. In cSCC TRIM16, cytoplasmic and nuclear expression is lower than normal lines due to
reduced TRIM16 stability. In cSCC TRIM16, bound and downregulated E2F1 are required for replication.
In normal cells, retinoids increase nuclear TRIM16 but not in retinoid-resistant cSCC. Overexpression of
TRIM16 in cSCC reduced migration.
TRIM16 plays a role in cSCC development and retinoid sensitivity.
[60] MET1, MET4
The flavonoid luteolin induced caspase-dependent cell death in cSCC. No cytotoxicity occurred in normal
cell lines. Luteolin-induced apoptosis was accompanied by Akt signalling inhibition. Sensitivity
decreased with tumour progression, with MET1 more sensitive to luteolin than MET4. Luteolin stimulates
autophagy in MET4 cells. In blocking autophagy, luteolin-induced apoptosis in MET4 was enhanced.
[32] SCCIC1
Expression of full-length type VII collagen in RDEB fibroblasts retards SCCIC1 growth and invasion
compared to growth and invasion facilitated by RDEB fibroblasts expressing empty vectors. Matrix
composition in RDEB patients provides a tumour permissive environment, with type VII collagen directly
regulating cancer-associated fibroblast protein secretion and cSCC progression.
[61] PM1, MET1, MET4
Sensitivity to apoptosis induced by UVB or oxidative stress differs between isogenic cell lines compared to
cisplatin-induced apoptosis. MET1 was most sensitive to UVB- and oxidative stress-mediated apoptosis,
with PM1 being the most resistant to apoptosis induction.
[62] MET1, SCCIC1
Axl knockdown in MET1 cells leads to ALDH1 cancer stem marker downregulation, CTGF, TWIST and
VIM EMT marker downregulation, and E-cadherin upregulation. Subpopulations of MET1 cells
expressing higher levels of cancer stem marker CD44 have correspondingly higher levels of Axl
expression. Morphological and cell–cell interaction changes occur with Axl knockdown.
Chemotherapeutic drug-induced cell death was inhibited by Axl expression.
[63] MET1, MET2, MET4, SCCT8, SCCIC8,SCCIC18, SCCIC19
The actin regulatory scaffold protein Eps8 is elevated in cSCC compared to normal skin. There were no
differences in Eps8 levels based on cSCC progression or immune status.
Eps8 in cSCC forms as a complex with focal adhesion kinase (FAK) at focal adhesions, promoting
actin-associated cancer phenotypes, including direction sensing and invasive migration. In the absence of
FAK, Eps8 is co-recruited with active Src. This provides a role for Eps8 as a mediator of intracellular
kinase fate in cSCC.
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[64] SCCT1, SCCT2, SCCT8, SCCIC1, MET1,SCCIC1MET, MET4
The SLCO1B3 gene, encoding the anion transporter frequently-mutated in cancer, OATP1B3, is
upregulated in RDEB cSCC and UV-induced cSCC compared to normal keratinocytes. With the exception
of SCCT8, all cSCC cell lines showed lower expression of SLCO1B3 compared to RDEB cSCC
keratinocytes. Compared to normal keratinocytes, OATP1B3 is expressed in cSCC keratinocytes; however,
membrane-localised expression is only readily detected in 3D cultures, mouse xenografts or in
OATP1B3-overexpressing 2D cultures. COL7A1 knockdown increases SLCO1B3 expression in SCCT8
cells. SLCO1B3 expression was also regulated by COL7A1 and ELMO2 in cSCC cells.
[65] MET1, MET2, MET4 Flightless I is elevated in cSCC lines compared to HaCaT cell line controls. There was no significantdifference in expression between isogenic lines MET1, MET2 and MET4.
[66] SCCIC1
Type VII collagen knockdown in SCCIC1 cells reduces cell–cell adhesion, increases blood vessel formation
by increased vascular endothelial growth factor (VEGF) secretion, increases invasion, and reduces
differentiation in cellular, organotypic and xenograft studies.
[41]
SCCIC1, SCCIC8, SCCIC12, SCCIC18,
SCCIC19, SCCT1, SCCT2, SCCT8, PM1, MET1,
MET4, SCCT9, SCCT10, SCCT11
Identification of frequent TGFBR1/2 mutations in human vemurafenib-induced skin lesions and in
sporadic cSCC. LGR5+ stem cells may act as origins for cSCC, driven by RAS/RAF/MAPK pathway
hyperactivation or TP53 mutation (coupled with reduction in TGFb signalling). The TGFBR2-mutant cell
lines SCCIC8 and SCCIC12 failed to respond to exogenous TGFb stimulation.
[27] SCCT2, SCCT8, SCCIC1
MEK inhibition results in senescence, but not apoptosis. Sensitivity to MEK inhibition was seen across all
lines at high concentration, low concentration-response between lines was heterogenous. MEK inhibition
may be a basis for molecularly targeted cSCC chemoprevention and therapy.
[67] SCCIC18
Activated SMAD2/3 was significantly reduced in perilesional cSCC and, to a greater extent, lesional cSCC
tissue. Increased tumour thickness inversely correlates with phospho-SMAD presence. Lines were used
for IHC antibody validation.
[37] MET1 (SCCT), MET4 (SCCTMet), SCCIC1,SCCIC1Met
Continuous treatment with the ubiquitin E1 inhibitor MLN7243 selectively killed MET1 and SCC IC1MET
cells. The latter cells were resistant to the inhibitor bortezomib. SCCIC1 cells were susceptible to
bortezomib pulses but highly resistant to MLN7243. Bortezomib-resistant cells can be sensitive to
MLN7243. Generally, pulse proteasome inhibitor exposure kills cSCC cells more effectively than extended
exposure. C-MYC-dependent pro-apoptotic protein NOXA upregulation confers inhibitor susceptibility
for rapid BAK-dependent death.
[68] T1, T8, MET1, MET4
Early stage T1 demonstrates the greatest proliferative response to IL-22 treatment. cSCC proliferation was
inhibited by JAK1/2 inhibitor ruxolitinib in vitro with tumour size reduction in vivo; however, this was
demonstrated in the A431 cSCC epidermoid carcinoma line only and not in T1, T8, MET1 or MET4 lines.
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[3] All lines (nomenclature consistent)
Whole exome sequencing analysis confirmed COSMIC mutation signature 7 was present in all lines.
Signature 32 was present in eight lines (four patients), all immunosuppressed and receiving azathioprine.
PM1, MET1/2/4 and T9 (all isogenic lines) showed similar mutational signatures. MET4 had additional
signature 26 associated with defective DNA mismatch repair. Altered mismatch repair genes are found in
all cSCC cell lines, but none correlate with signature 26.
[38]
MET1 (SCCT), MET4 (SCCTMet), SCCT1,
SCCT2, SCCT8, SCCT10, SCCT11, SCCIC1,
SCCIC1Met, SCCIC8, SCCIC12, SCCIC18
Spliceosome suppression has potential as a cSCC treatment. Endogenous C-MYC expression in cSCC cells
plays a role in conferring spliceosome inhibition-sensitivity and can act as a determinant of cSCC
sensitivity to spliceosome targeting. Mutant p53 depletion does not attenuate
spliceosome-inhibition-induced cell death in cSCC cells.
[69] MET1, IC1 Dual-action lysine specific demethylase 1- and histone deacetylase- inhibitor, coined Corin, exhibitsanti-proliferative activity in cSCC lines, compared to mono-functional inhibitors alone.
[70] MET1, MET4, IC8 The HDAC-inhibitor MS-275 potently inhibits the proliferation of MET4, MET1 and IC8 cells. MS-275 alsoinduced expression of p21 in cSCC cells.
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